ATF2 and prostate carcinoma: We also revealed that some prostate cancer-associated SPOP mutants show impaired binding to ATF2 proteins, resulting in impaired proteasomal degradation and accumulation of ATF2 in prostate cancer cell lines and cancer specimens, which partly contributes to SPOP inactivation-induced prostate cancer cell migration and invasion.